Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Amplia Therapeutics Ltd. ( (AU:ATX) ) has issued an update.
Amplia Therapeutics Ltd. presented interim data from its ACCENT trial at the AACR annual meeting, showcasing the promising efficacy of its FAK inhibitor, narmafotinib, in combination with chemotherapy for advanced pancreatic cancer. The data indicates that narmafotinib is well tolerated and shows better outcomes compared to chemotherapy alone, with a higher disease control rate and longer median duration on trial. This development could enhance Amplia’s positioning in the oncology market and provide new hope for stakeholders involved in pancreatic cancer treatment.
More about Amplia Therapeutics Ltd.
Amplia Therapeutics Ltd. is a biotechnology company focused on developing treatments for cancer. Its primary product, narmafotinib (AMP945), is a FAK inhibitor targeting pancreatic cancer, with Fast-Track and Orphan Drug Designation from the US FDA.
YTD Price Performance: -14.63%
Average Trading Volume: 23,462
Technical Sentiment Signal: Buy
Current Market Cap: $12.63M
For an in-depth examination of ATX stock, go to TipRanks’ Stock Analysis page.